ClinicalTrials.gov
ClinicalTrials.gov Menu

Once-Daily Oral Avatrombopag Tablets Used in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00914927
Recruitment Status : Completed
First Posted : June 5, 2009
Results First Posted : January 23, 2018
Last Update Posted : January 23, 2018
Sponsor:
Information provided by (Responsible Party):
Eisai Inc.

June 4, 2009
June 5, 2009
December 5, 2017
January 23, 2018
January 23, 2018
May 2009
November 11, 2011   (Final data collection date for primary outcome measure)
Percentage of Participants Experiencing Response [ Time Frame: Day 8 (Visit 5, EOT) ]
Platelet counts (PC) were determined from blood draws. A responder is defined as a participant having an increase of at least 20,000/mm^3 PC from Baseline and a PC greater than 50,000/mm^3 at least once during Day 4 through Day 8. Missing PC assessments at any given time point was considered to be a non-response at that point and were not estimated. For PC measurements taken after the last dose day (end of treatment (EOT)), the postdose windows applied. If there was more than one PC within the same analysis visit window, the following selection rules were applied sequentially to determine which PC was used for that time point: 1) the PC that was closer to the target date was used, 2) if PC were equal-distance in days from the target day, the later one based on measurement date and time was used, and 3) if there was more than one PC on the same day, if it was a baseline record, the largest one was used; if it was a postbaseline record, the smallest one was used.
Proportion of responders (i.e., a responder is defined as a subject having an increase of at least 20,000/mm^3 platelet count from baseline and a platelet count >/= 50,000/mm^3, at least once during Day 4 through Day 8). [ Time Frame: Day 4 through Day 8. ]
Complete list of historical versions of study NCT00914927 on ClinicalTrials.gov Archive Site
  • Change in Platelet Count on Day 8 (Visit 5 and/or End of Treatment) From Baseline [ Time Frame: Day 8 (Visit 5, EOT) ]
    Platelet counts were determined from blood draws. Missing PC assessments at any given time point was considered to be a non-response at that point and were not estimated. For PC measurements taken after the last dose day (EOT), the postdose windows applied. If there was more than one PC within the same analysis visit window, the following selection rules were applied sequentially to determine which PC was used for that time point: 1) the PC that was closer to the target date was used, 2) if PC were equal-distance in days from the target day, the later one based on measurement date and time was used, and 3) if there was more than one PC on the same day, if it was a baseline record, the largest one was used; if it was a postbaseline record, the smallest one was used.
  • Percentage of Participants Experiencing Dose-response by Visit [ Time Frame: Day 4 (Visit 3), Day 6 ( Visit 4), Day 8 (Visit 5, EOT), 3 Day Post Last Dose (Visit 6), and 7 Day Post Last Dose (Visit 7) ]
    Platelet counts were determined from blood draws. Missing PC assessments at any given time point was considered to be a non-response at that point and were not estimated. For PC measurements taken after the last dose day (EOT), the postdose windows applied. If there was more than one PC within the same analysis visit window, the following selection rules were applied sequentially to determine which PC was used for that time point: 1) the PC that was closer to the target date was used, 2) if PC were equal-distance in days from the target day, the later one based on measurement date and time was used, and 3) if there was more than one PC on the same day, if it was a baseline record, the largest one was used; if it was a postbaseline record, the smallest one was used.
  • Percentage of Participants Who Achieved a Platelet Count Greater Than 75,000/mm^3 on Day 4 [ Time Frame: Day 4 (Visit 3) ]
    Platelet counts were determined from blood draws. Missing PC assessments at any given time point was considered to be a non-response at that point and were not estimated. For PC measurements taken after the last dose day (EOT), the postdose windows applied. If there was more than one PC within the same analysis visit window, the following selection rules were applied sequentially to determine which PC was used for that time point: 1) the PC that was closer to the target date was used, 2) if PC were equal-distance in days from the target day, the later one based on measurement date and time was used, and 3) if there was more than one PC on the same day, if it was a baseline record, the largest one was used; if it was a postbaseline record, the smallest one was used.
  • Percentage of Participants Who Achieved a Platelet Count Greater Than 100,000/mm^3 on Days 4 and 8 [ Time Frame: Day 4 (Visit 3) and Day 8 (Visit 5, EOT) ]
    Platelet counts were determined from blood draws. Missing PC assessments at any given time point was considered to be a non-response at that point and were not estimated. For PC measurements taken after the last dose day (EOT), the postdose windows applied. If there was more than one PC within the same analysis visit window, the following selection rules were applied sequentially to determine which PC was used for that time point: 1) the PC that was closer to the target date was used, 2) if PC were equal-distance in days from the target day, the later one based on measurement date and time was used, and 3) if there was more than one PC on the same day, if it was a baseline record, the largest one was used; if it was a postbaseline record, the smallest one was used.
  • Change in platelet count from baseline on Day 8 or at end of treatment; dose-response of E5501 for platelet count elevation; proportion of subjects who achieve a platelet count >50,000/mm^3 on Day 4. [ Time Frame: Day 4 through Day 8. ]
  • Proportion of subjects who achieve a platelet count >100,000/mm^3 on Days 4, 8 or at end of treatment. [ Time Frame: Day 4 through Day 8. ]
Not Provided
Not Provided
 
Once-Daily Oral Avatrombopag Tablets Used in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures
A Phase 2, Randomized, Multicenter, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy, Safety, and Population Pharmacokinetics of Once-Daily Oral E5501 Tablets Used Up to 7 Days in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures
The purpose of this study is to evaluate the efficacy of once-daily Oral avatrombopagin subjects with chronic liver diseases and thrombocytopenia prior to elective surgical or diagnostic procedures, to evaluate the safety of short-term administration of avatrombopag and to evaluate the pharmacokinetics (PK) of E5501.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Thrombocytopenia Related to Chronic Liver Disease
  • Drug: Avatrombopag
    Avatrombopag first Dose 80 mg followed by 10 mg a day for up to 6 additional days
  • Drug: Avatrombopag
    Avatrombopag first Dose 80 mg followed by 20 mg a day for 3 days and then Placebo for 3 additional days
  • Drug: Placebo
    Placebo or inactive substance once a day for up to 7 days
  • Experimental: 1
    Intervention: Drug: Avatrombopag
  • Experimental: 2
    Interventions:
    • Drug: Avatrombopag
    • Drug: Placebo
  • Placebo Comparator: 3
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
130
132
December 21, 2011
November 11, 2011   (Final data collection date for primary outcome measure)

Key Inclusion Criteria:

  1. Males or females ≥ 18 years of age
  2. Thrombocytopenia (defined as a platelet count ≥ 10,000 - ≤ 50,000 (+15%)/mm^3 )
  3. Model for End-Stage Liver Disease (MELD) scores ≤ 24
  4. Chronic liver diseases due to one of the following three etiologies:

    Chronic Viral Hepatitis from one of the following categories

    • Chronic Hepatitis C (defined as the presence of anti-hepatitis C virus [HCV] antibodies and/or detectable serum HCV ribonucleic acid [RNA] levels)
    • OR chronic Hepatitis B (defined as the presence of hepatitis B surface antigen [HBsAg] and/or detectable serum hepatitis B virus [HBV] deoxyribonucleic acid [DNA])
    • OR chronic Hepatitis B and C co-infection (as defined by the above bullet points)
    • OR chronic Hepatitis C and history of alcohol abuse
    • OR chronic Hepatitis B and history of alcohol abuse

    NASH diagnosed as:

    • absence of serologic evidence of viral hepatitis and
    • convincing evidence of a history of minimal or no alcohol consumption, and
    • histologic picture of steatohepatitis OR
    • when histology is unavailable, then clinical, radiographic and laboratory evidence of NASH

    Alcoholic liver disease diagnosed as:

    • absence of serologic evidence of viral hepatitis and
    • history of heavy alcohol consumption and
    • histologic picture of alcoholic liver disease OR
    • when histology is unavailable, then clinical, radiographic and laboratory evidence of hepatitis combined with years of excessive alcohol intake
  5. Subjects who are scheduled to undergo an elective invasive procedure between 1 to 4 days post last dose of study drug.
  6. Adequate renal function as evidenced by a calculated creatinine clearance ≥50 mL/minute per the Cockcroft and Gault formula
  7. Life expectancy ≥3 months

Key Exclusion Criteria:

  1. Hepatic encephalopathy that cannot be effectively treated.
  2. Platelet transfusion within 7 days prior to the first dose of study drug
  3. Received blood products, eg, FFP and cryoprecipitate 7 days prior to the first dose of study drug
  4. Have surgical or diagnostic procedure scheduled during the Randomization Phase (Day 1 to Day 8) of this study
  5. Interferon use within 2 weeks of Day 1
  6. Hormonal contraceptive use within 60 days of study entry
  7. History of human immunodeficiency virus (HIV) infection
  8. Any prohibited concomitant medications or therapy that cannot be discontinued by Visit 1
  9. Active alcohol abuse, active alcohol dependence syndrome, drug abuse, or drug dependence within 6 months of the study start (unless participating in a controlled rehabilitation program)
  10. Acute alcoholic hepatitis (chronic alcoholic hepatitis is allowed) within 6 months of the study start
  11. History of any primary hematologic disorder
  12. History of arterial or venous thrombosis, including thrombosis of any part of the splenic-mesenteric system
  13. Any evidence of current portal vein thrombosis (PVT) as detected by Doppler sonography or appropriate MRI/CT imaging at Screening and/or within approximately 30 days prior to Screening
  14. Any acute/active bleeding (gastrointestinal [GI], central nervous system [CNS], etc)
  15. Uncompensated congestive heart failure (New York Heart Association [NYHA] Class III or IV)
  16. Pre-diagnosed Immune Thrombocytopenic Purpura (ITP)
  17. History of Myelodysplastic Syndrome (MDS)
  18. Females who are pregnant (positive β-hCG test ) or breastfeeding
  19. Current use of recreational drugs
  20. Post-transplant patients
  21. Subjects who have participated in another investigational trial within 30 days prior to Visit 1.
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00914927
E5501-G000-202
Not Provided
Not Provided
Not Provided
Eisai Inc.
Eisai Inc.
Not Provided
Study Director: Tim Jenkins Eisai Inc.
Eisai Inc.
January 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP